ReviewCurrent urology2026
Comparative analysis of male stress urinary incontinence treatments: A review of efficacy, safety, and clinical outcomes.
Review in Current urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Male stress urinary incontinence (MSUI) is a distressing condition that often results from radical prostatectomy, transurethral resection of the prostate, or other pelvic procedures. Despite the limitations of artificial urinary sphincters they have historically been considered the gold standard. Emerging treatments offer varying efficacies and safety levels. This study aimed to evaluate and compare the efficacy, safety, and clinical outcomes of current MSUI treatment modalities, including artificial urinary sphincters, adjustable transobturator male system (ATOMS), Pro Adjustable Continence Therapy, AdVance Non-adjustable Male Sling System, and duloxetine. Materials and methods: PubMed, covering prospective and retrospective analyses of MSUI treatments in postprostatectomy patients, was searched for relevant studies published between 2006 and 2024. Data on treatment efficacy (dry matter rate, improvement rate, and reduction in incontinence severity) and safety outcomes (complication and explanation rates) were extracted. Results: A total of 46 studies comprising 7841 patients were analyzed. Artificial urinary sphincters demonstrated the highest dryness rate (72.03%), whereas ATOMS had the highest improvement rate (85.56%) and the lowest surgical explantation risk (9.45%). Pro Adjustable Continence Therapy and AdVance yielded moderate efficacy, whereas duloxetine had the lowest complication rate (18.79%). Conclusions: Artificial urinary sphincters may be the most effective treatment for dryness, whereas ATOMS could offer high improvement rates with a lower risk of explantation and complications. Duloxetine demonstrated a strong safety profile as a pharmacological option, although the evidence remains limited. Given the heterogeneity of the existing studies, future prospective randomized trials are needed to refine treatment selection and optimize MSUI management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.